Latest news with #Intuitive
Yahoo
27-05-2025
- Business
- Yahoo
30 years of Innovation and Impact: Dan Larson's Inspiring Story
Intuitive Patient Day L to R Abhishek Biswas, MD, Federico Barbagli, and Dan Larson view an Ion Endoluminal System Intuitive Patient Day Dan Larson at a da Vinci 5 console at Intuitive in Sunnyvale CA L to R Dan Larson and Baiya Krishnadasan, MD Dan Larson, Cindy Larson, and Dr. Abhishek Biswas tour Intuitive's facilities in Sunnyvale, CA. SUNNYVALE, Calif., May 27, 2025 (GLOBE NEWSWIRE) -- When Seattle resident Dan Larson was diagnosed with lung cancer in 2023, his only exposure to robotic technology was through his work as a quality engineer at Boeing. He could never have imagined that robotic technology made by Intuitive, the pioneer of robotic-assisted surgery, would one day play a pivotal role in his health care. Having experienced the loss of his father to lung cancer, Dan was determined to overcome his own diagnosis and enjoy his retirement with his family. Under the care of clinicians at MultiCare Tacoma General Hospital in Washington, Dan underwent two robotic lung biopsies with the Ion Endoluminal System, Intuitive's robotic-assisted bronchoscopy platform, followed by a robotic-assisted lobectomy—removal of part of the lung— with the da Vinci 5 system, Intuitive's next-generation multiport robotic system. Following his successful procedures, Intuitive invited Dan and his wife Cindy, and his physicians, Abhishek Biswas, MD and Baiya Krishnadasan, MD, FACS, both from Tacoma General, to join the engineers, manufacturers, and other Intuitive employees who designed the technology that helped change his life to share his story as the company marks 30 years since its founding. 'When you've seen a loved one go through what I saw my father go through, you're willing to do anything if it means you will get better. I was lucky to have experienced doctors with the best technology near me, and from New Year's Eve to today, it's been a great recovery,' said Dan. 'To other people who may think they're in a similar situation, don't wait to get checked, get your answers, and have it taken care of,' said Dan. Dan spent his career dedicated to quality as a quality assurance investigator at Boeing, so the opportunity to see a behind-the-scenes manufacturing tour at Intuitive was especially meaningful. He witnessed the precision and dedication that goes into building the Ion and da Vinci systems, the technologies used in his care. Dr. Abhishek Biswas, who performed Dan's two Ion biopsies - one that resulted in a diagnosis in 2023 and then to detect local recurrence in 2024 - demonstrated the system to Dan and showed him the 3D navigation path of his own lungs that Dr. Biswas used for guidance when navigating to his target lung nodule. 'Dan was one of the first 25 patients I was able to biopsy with Ion, and without it, his cancer could have progressed to stage four. This technology is truly transformative. Thank you to Intuitive for developing something that is uniquely different and that has made a huge impact on my work, so I can do what is right for my patient,' said Biswas, interventional pulmonologist at MultiCare. Once Dan's lung cancer had been diagnosed, Dr. Baiya Krishnadasan, cardiothoracic surgeon at MultiCare, used the da Vinci 5 system to remove part of his lung on New Year's Eve 2024. "Dan's case is truly heartwarming and special. This was a very complex procedure with a high risk of complications, but with the use of the da Vinci 5 system, we performed a successful operation, and he was able to return home within 48 hours. His positive attitude is inspiring, and it's gratifying to see how well he's done. I'm excited to teach others how to use this remarkable technology," said Krishnadasan. MultiCare Health System was one of the first health systems in the Pacific Northwest to install a da Vinci 5 system. MultiCare has 30 da Vinci systems across various sites, including four da Vinci 5's, as well as four Ion Endoluminal Systems. 'Dan's story is powerful evidence of Intuitive's 30-year mission of putting patients first,' said Intuitive President Dave Rosa. 'Each day at Intuitive, we strive to solve hard problems so that clinicians can provide better outcomes for their patients. It was an honor to have Dan, his wife Cindy, and his physicians meet our teams to reinforce the connection between our employees and the patients that are taken care of using our technology,' said Rosa. 2025 marks Intuitive's 30th year developing robotic-assisted technology with the goal of improving patient outcomes, improving patient and care team experience, increasing access to minimally invasive care, and lowering the total cost to treat. In Intuitive's first three decades, surgeons performed nearly 17 million da Vinci procedures, and nearly 90,000 surgeons have been trained to use Intuitive's systems. To mark Dan's visit, Intuitive employees united to complete an internal Impact Wellness Challenge in collaboration with the Intuitive Foundation, raising $25,000. This amount will be donated by the Intuitive Foundation to St. Jude Children's Research Hospital, a charity chosen by Dan and his wife Cindy. Contact: Peper Long, About Intuitive Intuitive (NASDAQ: ISRG), headquartered in Sunnyvale, California, is a global leader in minimally invasive care and the pioneer of robotic surgery. Our technologies include the da Vinci surgical system and the Ion endoluminal system. By uniting advanced systems, progressive learning, and value-enhancing services, we help physicians and their teams optimize care delivery to support the best outcomes possible. At Intuitive, we envision a future of care that is less invasive and profoundly better, where disease is identified early and treated quickly, so that patients can get back to what matters most. About Ion Ion is Intuitive's robotic-assisted platform for minimally invasive biopsy in the lung. The system features an ultra-thin, ultra-maneuverable catheter that allows navigation far into the peripheral lung and provides the unprecedented stability necessary for precision in biopsy. About da Vinci Surgical Systems There are several models of the da Vinci Surgical System. The da Vinci surgical systems are designed to help surgeons perform minimally invasive surgery and offer surgeons high-definition 3D vision, a magnified view, and robotic and computer assistance. They use specialized instrumentation, including a miniaturized surgical camera and wristed instruments (i.e., scissors, scalpels, and forceps) that are designed to help with precise dissection and reconstruction deep inside the body. Important Safety Information Patients should talk to their doctor to decide if surgery with a da Vinci system is right for them. Patients and doctors should review all available information on nonsurgical and surgical options and associated risks in order to make an informed decision. Serious complications may occur in any surgery, including surgery with a da Vinci system, up to and including death. For important safety information, including surgical risks and considerations, please refer to For product intended use and/or indications for use, risks, cautions, and warnings and full prescribing information, refer to the associated user manual(s) or visit The demonstration of safety and effectiveness for the representative-specific procedures was based on evaluation of the da Vinci 5 system as a surgical tool and did not include evaluation of outcomes related to the treatment of cancer (overall survival, disease-free survival, local recurrence) or treatment of the patient's underlying disease or condition. Device usage in all surgical procedures should be guided by the clinical judgment of an adequately trained surgeon. Individuals' outcomes may depend on a number of factors—including but not limited to—patient characteristics, disease characteristics, and/or surgeon experience. Photos accompanying this announcement are available at: in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
23-05-2025
- Business
- Yahoo
Cost cuts, production shifts: How medtech firms are managing tariffs
This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Medical device makers are leaning on their global manufacturing footprints to shift production and inventory as they navigate fluid tariff policies. Large medtech manufacturers are mostly avoiding potentially costly strategies such as reducing sales staff or investments in research and development, analysts said in interviews with MedTech Dive. Price increases are a last resort. Rather, companies are focused on managing discretionary expenses and exemptions. 'They are not taking away from their sales team, advertising or R&D,' said Rebekuh Eley, healthcare analyst at tax and consulting firm RSM. 'They're moving ahead with that. It's more on the operational side.' Intuitive Surgical, for example, manufactures about 80% of its surgical instruments and accessories in Mexico. However, most of the products are certified under the U.S.-Mexico-Canada Agreement and therefore exempt from current import tariffs, CFO Jamie Samath said in an April earnings call. Intuitive reduced its 2025 profit margin forecast due to tariff pressures. Nevertheless, Samath said the company is pushing ahead with manufacturing expansion plans, including increasing instrument production in Mexico, to support its growth in the medium term. The surgical robot maker recently opened two manufacturing facilities in California that will also house R&D teams, along with a factory in Georgia. New plants are planned in Germany and Bulgaria. Intuitive, said outgoing CEO Gary Guthart, will 'optimize our production costs and rebalance product flows within our existing manufacturing and supply chain footprint as policies begin to stabilize.' Other device makers, such as Boston Scientific and Abbott, said they are expanding U.S. manufacturing to support long-term growth while taking more immediate actions to mitigate tariff exposure. Boston Scientific recently opened a new site in Georgia and increased manufacturing investments in both Minnesota and Malaysia, said CEO Mike Mahoney. The company expects to absorb a $200 million hit this year from tariffs. Abbott, which anticipates a tariff impact of 'a few hundred million dollars' in 2025, is investing in manufacturing and R&D in Illinois and Texas to expand its transfusion business that makes devices to screen blood donations, according to CEO Robert Ford. Meanwhile, Siemens Healthineers last week unveiled $150 million in new projects to expand production in the U.S., including relocating manufacturing operations for its Varian business to California from Mexico. And Roche Diagnostics this month announced a $550 million expansion in Indianapolis to produce continuous glucose monitors. Cardinal Health was one company that announced layoffs as a mitigation strategy for a tariff hit of up to $300 million. While some firms will be less pressured by tariffs than others, top medtech companies together project a financial impact from tariffs totaling more than $2 billion, based on the current 10% general tariff rate and higher China-specific duties, according to a recent analysis by PitchBook. The report cited research that found more than $60 billion worth of medical devices and components are manufactured overseas and imported into the U.S. annually. For startups, tariffs are likely to raise input costs and extend time to profitability, with the surrounding uncertainty bringing even more challenges that could delay initial public offerings until broader market conditions stabilize, PitchBook said. Last week, the U.S. and China rolled back for 90 days a large portion of the steep tariffs each imposed on the other in recent months. Before that, many medtech companies said the effects of the U.S.-China trade war accounted for a significant part of the impact on their outlooks. With the new pause, 'the most pessimistic outcome seems to be off the table,' said PitchBook healthcare analyst Aaron DeGagne. RSM's Eley said medtech companies will look at passing costs on to customers only after they've exhausted all other measures. 'They're trying to do what they can do internally first, without raising prices, and then they will raise the prices,' she said. On Wednesday, Medtronic's new CFO, Thierry Piéton, said the company built its expectations on two potential scenarios. The low end of its projected tariff impact assumes current bilateral U.S. and China tariffs, in place during the pause, remain throughout its fiscal 2026, which began in late April. The high end assumes the higher rates resume after the pause. The company ultimately forecast a tariff charge in a range of $200 million to $350 million for the year. In another development, Treasury Secretary Scott Bessent this week said the U.S. will reinstate other country-specific reciprocal tariffs first announced April 2 if deals are not reached during a 90-day pause. As companies get a better handle on tariff-related costs, including whether customers grow more cautious about capital equipment purchases, some could revise initial financial guidance, PitchBook's DeGagne said. Those that gave forecasts in wide ranges have more flexibility, he added, but 'at some point, they need to provide a better number.' Whether the 90-day pause on new tariffs with China is 'an uncertainty-clearing event' is far from clear, Morgan Stanley analysts said in a report Sunday. 'Trade tensions are likely to remain elevated,' the analysts wrote. 'The administration is still investigating tariffs on pharmaceuticals, semiconductors, and copper, among other products. It is also unclear if the template of negotiations between the US and China can work for other regions, especially Europe.' Recommended Reading US signals reciprocal tariffs will return for some countries Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
19-05-2025
- Business
- Yahoo
One of the Best Space Stocks Just Reported a Big Change, and Its Stock Popped 35% in 1 Day
Investors flocked to Intuitive Machines after the company reported a loss and a revenue decline for Q1. Management reassured investors it is on track to hit its revenue target for the year. Intuitive Machines also promised to "incorporate IM-2 lessons learned" and hopefully land its next lunar lander right side up. 10 stocks we like better than Intuitive Machines › Every so often, you're right about a stock, and it makes you nervous about how long you can keep on being right. That's kind of how I feel looking at Intuitive Machines (NASDAQ: LUNR) stock right now. Back at the start of the month, if you recall, I said Intuitive Machines stock was a buy and could pop after earnings. And after Intuitive reported earnings this week, the stock did indeed go up. In fact, it went up a lot, surging nearly 35% at one point on the day after earnings, and still up nearly 28% as I type these words. And now I'm honestly not sure this stock is still a buy. Intuitive Machines' Q1 earnings report didn't feature a lot in the way of "earnings," necessarily, and it only reported $62.5 million in revenue. According to the good folks at The Fly, however, that was less than the $66.1 million in revenue that Wall Street analysts were predicting. It was also a 15% decline from the company's $73.2 million in Q1 2024 revenue. Operating costs of $72.6 million ate up all the company's revenue and left Intuitive with a $10.1 million operating loss for Q1. On the bottom line, losses were $11.4 million, or $0.11 per share, according to data from S&P Global Market Intelligence. That's the bad news. Now, here's the good: Intuitive Machines just announced a big change in its cash situation. Intuitive Machines generated positive operating cash flow for the first time in nearly two years in Q1 -- $19.4 million, and reported quarterly positive free cash flow of $13.3 million. The company is still FCF-negative for the past 12 months, and most analysts don't expect to see the company generating FCF consistently for another few years -- but Q1 improved its TTM performance considerably, and Intuitive now has at least a chance of reporting its first full year of positive FCF in 2025. Yes, a small chance. Most analysts still see Intuitive burning cash this year, but less than $2 million. But Intuitive is due to receive "IM-2 success payments" in Q2, which could potentially push the company over the finish line. Management is forecasting between $250 million and $300 million in total revenue this year, right in line with analyst forecasts. In other "IM-" news, the company confirmed that its next moon landing, IM-3, is on track to take place in the first half of next year, "and will incorporate IM-2 lessons learned" -- which hopefully means Intuitive has figured out how to keep its landers from toppling over after landing on the moon. Intuitive is also making progress on its much bigger, much more valuable, $4.8 billion contract to build a Near Space Network for satellite communication between the Earth and moon, completing two "milestones" and receiving funding for two more. With Intuitive Machines stock up so much (again, about 28% over just the past few days), and up so quickly after earnings, I'm a bit less enthusiastic about buying more shares (I already own a few) now that the good news is out. True, the chance that Intuitive might report positive full-year free cash flow in 2025 -- a full three years earlier than Wall Street was expecting -- could be another great catalyst to lift the stock. That said, the main project I'm counting on to drive the company's success is the $4.8 billion NSN NASA contract. That one stretches over 10 years, and appears to be rolling out only slowly, with only $9 million in revenue booked in Q1, and only $18 million more coming in Q2. It's a big-dollar contract, with a long timeline. These two factors combined create a risk that a budget-constrained NASA might be forced to cancel the contract at some point in the future, dramatically limiting growth prospects for Intuitive Machines -- and potentially crashing the stock as well. While I don't think that will happen, it's a risk, and it's one investors in Intuitive Machines stock should keep in mind. The best way to limit that risk is to buy Intuitive Machines stock on a pullback, when it looks cheap again. Before you buy stock in Intuitive Machines, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Intuitive Machines wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $642,582!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $829,879!* Now, it's worth noting Stock Advisor's total average return is 975% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of May 12, 2025 Rich Smith has positions in Intuitive Machines. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. One of the Best Space Stocks Just Reported a Big Change, and Its Stock Popped 35% in 1 Day was originally published by The Motley Fool Sign in to access your portfolio
Yahoo
15-05-2025
- Business
- Yahoo
Intuitive Announces CEO Transition Effective July 1, 2025
President Dave Rosa promoted to CEOCurrent CEO Gary Guthart to become executive chair of Intuitive's boardCurrent Board Chair Craig Barratt to become lead independent director SUNNYVALE, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Intuitive (NASDAQ: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced the promotion of President Dave Rosa to chief executive officer, effective July 1, 2025. At that time, current CEO Gary Guthart will become the executive chair of Intuitive's board of directors, and current Board Chair Craig Barratt will become lead independent director. Guthart will work closely with Rosa to support a smooth transition and will remain with Intuitive in a senior advisory capacity. 'Dave's appointment as CEO is the culmination of the Board's thoughtful succession planning, reflecting his instrumental role in establishing our strategy, guiding the development of our product pipeline, and expanding the company's global footprint. We are confident he's the right leader to drive the company's next chapter of growth,' said Intuitive Board Chair Craig Barratt. 'On behalf of Intuitive's board, we thank Gary for his leadership of our company. We are fortunate that he will continue to play an important role as our next executive chair,' continued Barratt. 'And, on behalf of our customers, we thank him for the role he has played in helping Intuitive pioneer advancements in robotic-assisted surgery that optimize care and deliver better patient outcomes.' 'It has been an honor and a privilege to serve as Intuitive's CEO for the past 15 years, working alongside our talented and dedicated employees as we seek to advance minimally invasive care for healthcare teams and their patients around the world. Together, we've developed products and services that have made a positive difference for care teams and millions of their patients,' said Guthart. 'Having worked closely with Dave for decades, I am confident that his patients-first focus and deep capability in guiding Intuitive's strategy, our designs, our product and service quality, and our operational excellence make him uniquely qualified to lead our business forward,' said Guthart. 'Gary's stewardship of Intuitive has had a significant impact on patients, clinicians, and hospitals. I thank him for his work and am honored to become the next Intuitive CEO,' said Rosa. 'We are at an exciting time with a significant opportunity to advance the work that customers care most about—the Quintuple Aim—improving patient outcomes, enhancing patient and care team experience, expanding patient access to care, and ultimately lowering the total cost to treat. I look forward to building on this work alongside the entire Intuitive team to deliver on these goals and drive value for all our stakeholders,' said Rosa. A 29-year veteran with Intuitive, Rosa first joined the company as its ninth employee in March 1996. Since then, he has held leadership positions across the business, including engineering, clinical and product development, marketing, regulatory and quality affairs, and the commercial organization. Among his achievements, Rosa founded Intuitive's first clinical engineering and endoluminal groups, leading to the development and commercialization of the da Vinci SP (single port) robotic-assisted surgical system and Ion robotic bronchoscopy system. He also launched the company's Future Forward group, which identifies and develops transformational new business opportunities. Rosa assumed the role of executive vice president and chief business officer in 2019, transitioning to chief strategy and growth officer three years later. Rosa has served as Intuitive's president since 2023 and became a member of the board of directors in 2024. 2025 marks Intuitive's 30th year developing robotic-assisted technology with the goal of improving patient outcomes, improving patient and care team experience, increasing access to minimally invasive care, and lowering the total cost to treat. In Intuitive's first three decades, surgeons performed nearly 17 million da Vinci procedures, and nearly 90,000 surgeons have been trained to use Intuitive's systems. Contact: Peper Long, IntuitiveGlobal Public Affairs 1-202-997-7373 About IntuitiveIntuitive (NASDAQ: ISRG), headquartered in Sunnyvale, California, is a global leader in minimally invasive care and the pioneer of robotic surgery. Our technologies include the da Vinci surgical system and the Ion endoluminal system. By uniting advanced systems, progressive learning, and value-enhancing services, we help physicians and their teams optimize care delivery to support the best outcomes possible. At Intuitive, we envision a future of care that is less invasive and profoundly better, where disease is identified early and treated quickly, so that patients can get back to what matters most. Forward-Looking StatementsThis press release contains forward-looking statements which relate to expectations concerning matters that are not historical facts. Statements using words such as 'estimates,' 'projects,' 'believes,' 'anticipates,' 'plans,' 'expects,' 'intends,' 'may,' 'will,' 'can,' 'could,' 'should,' 'would,' 'targeted,' 'potential,' and similar words and expressions are intended to identify forward-looking statements. These forward-looking statements are necessarily estimates reflecting the judgment of Intuitive's management and involve a number of risks and uncertainties that could cause actual results or impacts on its operations, financial performance, and business position to differ materially from those suggested by the forward-looking statements. These forward-looking statements include, but are not limited to, statements related to research and development of products and services, manufacturing of products, obtaining of regulatory approvals, technical and other performance of products and services, and making products and services available to more patients and health care professionals. These forward-looking statements should be considered in light of various important factors and involve known and unknown risks, uncertainties, and other factors, which may cause the actual results, performance, or achievements of Intuitive, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Important factors that could cause actual results to differ materially from those anticipated in the forward-looking statements include, among others, economic conditions in the geographic markets in which we operate, changes in governmental regulations, regulatory approval priorities, resources, and timelines, regulatory enforcement priorities, governmental investigations and civil litigation, and other factors discussed in Intuitive's Annual Reports and other filings with relevant securities regulators. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release and which are based on current expectations and are subject to risks, uncertainties, and assumptions that are difficult to predict, including those risk factors identified under the heading 'Risk Factors' in Intuitive's Annual Report on Form 10-K for the year ended December 31, 2024, as updated by its other filings with the U.S. Securities and Exchange Commission. Intuitive's actual results may differ materially and adversely from those expressed in any forward-looking statements, and it undertakes no obligation to publicly update or release any revisions to these forward-looking statements, except as required by law.
Forbes
14-05-2025
- Forbes
1 Hotel Hanalei Bay Review
Travelers visit the lush island of Kauai for its stunning views, abundant waterfall hikes and pristine beaches. Nestled on a north shore hillside in Princeville overlooking the Pacific, the 1 Hotel Hanalei Bay is ideally located whether you're a first-timer or a repeat visitor who wants to stay put and soak in its gorgeous surroundings. As a frequent visitor to Kauai, I always prefer staying on the quieter north shore thanks to its untouched feel and serene atmosphere. On a recent trip, I checked into the 1 Hotel Hanalei Bay with my family and found its signature blend of wellness, sustainability and understated luxury to fit right into the verdant locale. If you're planning a trip, here's what to know. divider Pool at the 1 Hotel Hanalei Bay. Mikkel Vang divider With an open-air design and foliage interspersed throughout, the 1 Hotel Hanalei Bay is tastefully adorned in neutral tones and textures, with décor that uses locally sourced and reclaimed materials. The grounds feature native-plant landscaping and a 7,400-gallon rainwater harvesting system, and all restaurants on site are certified Ocean Friendly by the Surfrider Foundation. A sprawling main pool on the ground level by the beach welcomes all guests and features plenty of shallow ledges and hot tub nooks, as well as a separate lagoon pool with waterfalls (adults can also enjoy the upper-level infinity pool). The beach is on a large bay that connects to Hanalei by water: It's so dense with coral that you're likely to spot sea creatures (think sea turtles and manta rays) even if you're not actively snorkeling. Open-air lobby at the 1 Hotel Hanalei Bay. AVABLU The Bamford Wellness Spa is a destination in itself, with 18 treatment rooms, as well as Touchless Therapies that include an ocean float room, hyperbaric oxygen chamber, infrared sauna and meditation pod. I booked the Intuitive Herbal Ritual, which combined a facial and massage and incorporated Kauai Pharmacy's excellent plant-based skincare products, ending with an application of tension-easing, warmed noni leaves. There are plenty of activities for families, from surfing and snorkeling to ohana nature walks and ukelele lessons (I still have the dried leis my son and I made in our oceanside ti leaf lei making class). Additional classes and events designed for a wide range of age groups are mapped out in the weekly Daylife calendar, and the hotel offers its own version of a kids club called Seedlings. divider The property has 252 rooms, including 51 suites, that have views of the ocean (looking out onto Hanalei Bay and beyond), mountains or a combination of both. With Kauai being known as the Garden Isle, there are no bad room views here. Ocean View King room at the 1 Hotel Hanalei Bay. Ryan Forbes We stayed in an Ocean View room that looked out onto rolling waves and waterfall-studded mountains. An abundant fruit basket and housemade banana bread welcomed us upon check-in, and I appreciated the little plaque on the dresser that encourages anyone who wants to lighten their suitcase for their return trip to leave behind items for donation. Rooms feature Nespresso machines, craft snacks, a variety of beverages and yoga mats. Our bathroom had a rainfall shower, Bamford bath products (infused with a fragrant blend of geranium, lavender, peppermint and tonka, crafted exclusively for 1 Hotel), and a very convenient filtered water tap (along with plenty of refillable aluminum water bottles to use during our stay). divider Dining options abound at the hotel; all of the menus feature seasonal produce sourced from local farmers and growers—some even from the rooftop chef's garden. The main restaurant, 1 Kitchen, serves breakfast (daily buffet or à la carte), lunch and dinner. Dishes are globally-inspired, with plenty of inventive vegetable-forward options along with mainstays like sourdough pull-apart buns, housemade pastas and fresh local catch. Aerial view of 1 Kitchen at the 1 Hotel Hanalei Bay. Mikkel Vang Although it's deemed a lounge, you can very well make a dinner out of an evening at Welina Terrace, which serves Japanese-inspired small plates, sushi rolls and a burnt cream gelato that I ordered more than once. Time your evening with the sunset and request a table on the terrace for insane views of Mount Makana and the rest of the bay. True to the hotel's wellness-focused theme, there are just as many locally inspired mocktails and low ABV drinks as there are signature cocktails (my favorite, the Kaua'i Tai, features a local macadamia nut orgeat topped with a lilikoi and hibiscus foam). Poolside food isn't typically the most impressive, but the Sandbox restaurant holds its own, offering everything from woodfired Neopolitan pizzas to ahi nachos and spicy poke bowls. The hotel also has a shave ice and gelato shop, juice bar that opens in the early hours (ideal for visitors still on mainland time), and the 1 Hotel's signature Neighbors cafe, serving açai bowls and grab-and-go breakfast and lunch fare. divider While the whole island of Kauai is worth exploring, my family likes to stay on the north shore thanks to its immediate proximity to dramatic coastlines and fantastic beaches, as well as its laid back vibe. The 1 Hotel's beachfront property is ideally located for plenty of outdoor activities, including paddleboarding, going on nature walks, or taking dips at Puu Poa or Hideaways beach. Nearby towns like Kilauea and Hanalei—as well as my favorite, Anini Beach—are less than a 20-minute drive away. A day trip to Waimea Canyon, nicknamed the 'Grand Canyon of the Pacific,' will take you about an hour and a half by car—the longest drive you can make on the island's main roads. It's definitely worth taking in the breathtaking Nāpali Coast, which can be accessed on foot (via the rigorous 11-mile Kalalau Trail), by boat, or on an aerial helicopter tour (which I highly recommend). When visiting Kauai, it's best to rent a car, as taxis and rideshare are not as prevalent as on some of the other islands. The 1 Hotel does have a small fleet of electric Audi e-trons available for guests to drive in the local area. divider Despite its name, the 1 Hotel Hanalei Bay is in Princeville, just over the bridge from the town of Hanalei. It's about a 45-minute drive from Lihue Airport (LIH).
